Alessandro Armuzzi

25.3k total citations · 1 hit paper
435 papers, 10.4k citations indexed

About

Alessandro Armuzzi is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Alessandro Armuzzi has authored 435 papers receiving a total of 10.4k indexed citations (citations by other indexed papers that have themselves been cited), including 293 papers in Genetics, 245 papers in Epidemiology and 159 papers in Surgery. Recurrent topics in Alessandro Armuzzi's work include Inflammatory Bowel Disease (290 papers), Microscopic Colitis (205 papers) and Eosinophilic Esophagitis (70 papers). Alessandro Armuzzi is often cited by papers focused on Inflammatory Bowel Disease (290 papers), Microscopic Colitis (205 papers) and Eosinophilic Esophagitis (70 papers). Alessandro Armuzzi collaborates with scholars based in Italy, United States and United Kingdom. Alessandro Armuzzi's co-authors include Antonio Gasbarrini, Luisa Guidi, Daniela Pugliese, Alfredo Papa, Filippo Cremonini, Giovanni Cammarota, Paolo Gionchetti, Carla Felice, Marcello Candelli and Sandro Ardizzone and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and PLoS ONE.

In The Last Decade

Alessandro Armuzzi

408 papers receiving 10.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders

2017 1.3k citations Sandro Ardizzone, Alessandro Armuzzi et al. Journal of Crohn s and Colitis profile →

Peers

Countries citing papers authored by Alessandro Armuzzi

Since Specialization

Citations

This map shows the geographic impact of Alessandro Armuzzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessandro Armuzzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessandro Armuzzi more than expected).

Fields of papers citing papers by Alessandro Armuzzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessandro Armuzzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessandro Armuzzi. The network helps show where Alessandro Armuzzi may publish in the future.

Co-authorship network of co-authors of Alessandro Armuzzi

This figure shows the co-authorship network connecting the top 25 collaborators of Alessandro Armuzzi. A scholar is included among the top collaborators of Alessandro Armuzzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessandro Armuzzi. Alessandro Armuzzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sessile Serrated Lesions in Inflammatory Bowel Disease: Hidden Players in Colitis-Associated Colorectal Cancer? 2025 ·Journal of Clinical Medicine ·Roberto de Sire, (unknown), (unknown), (unknown), Giulio Calabrese, (unknown), (unknown), Cristina Bezzio, Alessandro Armuzzi, Cesare Hassan, Alessandro Repici, Fabiana Castiglione, Sandro Ardizzone, Roberta Maselli	0
2	P535 Effectiveness of upadacitinib in patients with Ulcerative Colitis: a real-life, multicenter, Italian report 2024 ·Journal of Crohn s and Colitis ·(unknown), Nazario Bevilacqua, Roberto Gabbiadini, Cristina Bezzio, Antonio Ferronato, Simone Saibeni, Alessandro Armuzzi, Michele Comberlato, (unknown)	1
3	Prevalence, Risk Factors and Association with Clinical Outcomes of Malnutrition and Sarcopenia in Inflammatory Bowel Disease: A Prospective Study 2024 ·Nutrients ·Cristina Bezzio, (unknown), Davide Giuseppe Ribaldone, Maria Cappello, (unknown), Marta Vernero, (unknown), Laura Loy, (unknown), Stefania Ciminnisi, Gianpiero Manes, Alessandro Armuzzi, Simone Saibeni	5
4	Management of Clostridioides difficile infection: an Italian Delphi consensus 2024 ·Journal of Antimicrobial Chemotherapy ·Matteo Bassetti, Antonio Cascio, Francesco Giuseppe De Rosa, Marianna Meschiari, Roberto Parrella, Nicola Petrosillo, Alessandro Armuzzi, Flavio Caprioli, Francesco Dentali, (unknown), Alberto Pilotto, Umberto Restelli, Maurizio Sanguinetti	0
5	How comparative studies can inform treatment decisions for Crohn’s disease 2024 ·Expert Opinion on Biological Therapy ·Giuseppe Privitera, Cristina Bezzio, Arianna Dal Buono, Roberto Gabbiadini, Laura Loy, (unknown), (unknown), (unknown), Alessandro Armuzzi	1
6	P391 Relative association of bowel urgency clinically meaningful improvement or bowel urgency remission versus stool frequency remission and rectal bleeding remission with improvement in Inflammatory Bowel Disease Questionnaire scores in patients with moderately-to-severely active Ulcerative Colitis: An analysis from LUCENT-1 and LUCENT-2 phase 3 clinical trials 2023 ·Journal of Crohn s and Colitis ·B E Sands, B G Feagan, (unknown), (unknown), (unknown), (unknown), Stefanie Schreiber, Vipul Jairath, Alessandro Armuzzi	2
7	P205 Impact of histologic disease activity on long-term outcomes in patients with ileal pouch-anal anastomosis for ulcerative colitis 2023 ·Journal of Crohn s and Colitis ·Roberto Gabbiadini, Paola Spaggiari, Arianna Dal Buono, (unknown), Federica Furfaro, Ferdinando D’Amico, Alessandro Repici, Antonino Spinelli, Alessandro Armuzzi	1
8	Estimation of patients affected by inflammatory bowel disease potentially eligible for biological treatment in a real-world setting 2023 ·Digestive and Liver Disease ·Luca Degli Esposti, Valentina Perrone, Diego Sangiorgi, Stefania Saragoni, (unknown), Flavio Caprioli, Fernando Rizzello, Marco Daperno, Alessandro Armuzzi	1
9	Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study 2023 ·Journal of Clinical Medicine ·Ahmad Albshesh, (unknown), (unknown), Marie Truyens, Stephan R. Vavricka, (unknown), Daniela Pugliese, Edoardo Savarino, Eran Zittan, David Drobne, Xavier Roblin, Ariella Bar‐Gil Shitrit, Alessandro Armuzzi, Triana Lobatón, Nitsan Maharshak, Henit Yanai, Shomron Ben‐Horin, Uri Kopylov	4
10	A retrospective analysis of treatment patterns, drug discontinuation and healthcare costs in Crohn's disease patients treated with biologics 2023 ·Digestive and Liver Disease ·Luca Degli Esposti, Marco Daperno, (unknown), (unknown), Diego Sangiorgi, Edoardo Savarino, Franco Scaldaferri, (unknown), Andrea Serra, Valentina Perrone, Alessandro Armuzzi	8
11	P293 Insights from patients with Ulcerative Colitis on disease burden: Findings from a real-world survey in Europe 2022 ·Journal of Crohn s and Colitis ·Johan Burisch, AL Hart, Alessandra Oortwijn, Mona Aeysha Khalid, Fritha Hennessy, (unknown), R. Meadows, Haridarshan Patel, Alessandro Armuzzi	2
12	Nursing‐sensitive outcomes in adult inflammatory bowel disease: A systematic review 2021 ·Journal of Advanced Nursing ·Rocco Spagnuolo, (unknown), Daniele Napolitano, (unknown), (unknown), (unknown), Elisa Schiavoni, Laura Turchini, Gionata Fiorino, Simona Radice, Alessandro Armuzzi, Patrizia Doldo	7
13	Acute pancreatitis and parathyroid carcinoma: a case report and literature review 2021 ·SHILAP Revista de lepidopterología ·Mignini Irene, Marco Pizzoferrato, (unknown), Antonio Gasbarrini, G.L. Rapaccini, Alessandro Armuzzi	3
14	Challenges in Crohn’s Disease Management after Gastrointestinal Cancer Diagnosis 2021 ·Cancers ·Claudio Fiorillo, Carlo Alberto Schena, Giuseppe Quero, Vito Laterza, Daniela Pugliese, Giuseppe Privitera, Fausto Rosa, Tommaso Schepis, Lisa Salvatore, (unknown), (unknown), Laura Maria Minordi, Luigi Natale, Giampaolo Tortora, Alessandro Armuzzi, Sergio Alfieri	8
15	Sa1877 EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF SWITCHING FROM ORIGINATOR INFILIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN A LARGE COHORT OF IBD PATIENTS 2020 ·Gastroenterology ·Giuseppe Privitera, Daniela Pugliese, Barbara Tolusso, Elisa Gremese, Alfredo Papa, Luigi Giovanni Papparella, Antonio Gasbarrini, Gian Lodovico Rapaccini, Luisa Guidi, Alessandro Armuzzi	1
16	Serum triiodothyronine‐to‐thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients 2020 ·Alimentary Pharmacology & Therapeutics ·Lorenzo Bertani, Domenico Tricò, Daniela Pugliese, Giuseppe Privitera, Giuseppe Linsalata, Federico Zanzi, M.G. Mumolo, Brigida Barberio, Fabio Monzani, Santino Marchi, Luisa Guidi, Corrado Blandizzi, Alessandro Armuzzi, Francesco Costa	17
17	Histopathology of inflammatory bowel disease — Position statement of the Pathologists of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Group of Gastrointestinal Pathologists (GIPAD-SIAPEC) 2019 ·Digestive and Liver Disease ·Vincenzo Villanacci, Luca Reggiani Bonetti, Flavio Caprioli, Luca Saragoni, Tiziana Salviato, Claudia Mescoli, Gabriella Canavese, Stefania Manenti, (unknown), (unknown), Giuseppe Leoncini, Moris Cadei, Serena Battista, Alessandro Armuzzi	17
18	Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open 2019 ·Alimentary Pharmacology & Therapeutics ·Bruce E. Sands, Alessandro Armuzzi, John K. Marshall, James O. Lindsay, William J. Sandborn, Silvio Danese, Julián Panés, Brian Bressler, Jean‐Frédéric Colombel, Nervin Lawendy, Eric S. Maller, Haiying Zhang, Gary Chan, Leonardo Salese, (unknown), Amy Marren, Chinyu Su	65
19	Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti‐TNF alpha: 5‐year follow‐up study 2015 ·Alimentary Pharmacology & Therapeutics ·Daniela Pugliese, Luisa Guidi, Pietro Manuel Ferraro, Manuela Marzo, Carla Felice, Leonardo Celleno, Rosario Landi, (unknown), Fabrizio Pizzolante, I. De Vitis, Alfredo Papa, Gian Lodovico Rapaccini, Alessandro Armuzzi	85
20	Correction for Ahmad et al, The molecular classification of the clinical manifestations of Crohn's disease 2003 ·Murdoch Research Repository (Murdoch University) ·Tanvir Ahmad, Alessandro Armuzzi, M. Bunce, (unknown), (unknown), T. Orchard, Jonathan Crawshaw, Oliver Large, (unknown), Julia Cook, Martin Barnardo, Sue Cullen, KI Welsh, D P Jewell	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact